Method for treating pain in humans
OwnerEdward Leunginventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to Compound T62, pharmaceutically acceptable salts thereof, and their use in medicine as allosteric adenosine A1 receptor enhancers and uses including treatment of pain, for example, persistent chemical pain, meuropathic pain and acute pain states such as that induced by chemical irritation, gastrointestinal disturbance, migraine and all forms of headache. 1 (2-amino-4,5,6,7-tetahydro-1-benzothien-3-yl)(4-chlorophenyl)methanone
Claims26
A method of treating hyper-excited sensory nerve functions, comprising administering to a conscious human patient in need of treatment thereof a pharmaceutical composition comprising an effective amount of (2-Amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)(4-chlorophenyl) methanone or a pharmaceutically acceptable salt thereof in a dose of from 45 μg/kg to 1024 μg/kg.
A method of treating hyper-excited sensory nerve functions, comprising administering to a conscious human patient in need of treatment thereof a pharmaceutical composition comprising an effective amount of (2-Amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)(4-chlorophenyl) methanone or a pharmaceutically acceptable salt thereof in a dose of from 45 μg/kg to 1024 μg/kg and adenosine.
A pharmaceutical preparation for oral administration to a human for the reduction of neuropathic pain and inflammatory pain comprising (2-Amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)(4-chlorophenyl) methanone or a pharmaceutically acceptable salt thereof in dosage levels of from 45 μg/kg to 1024 μg/kg.
A pharmaceutical preparation for oral administration to a human for the reduction of neuropathic pain and inflammatory pain comprising (2-Amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)(4-chlorophenyl) methanone or a pharmaceutically acceptable salt thereof in dosage levels of from 45 μg/kg to 1024 μg/kg and further comprising adenosine.
A method of treating hyper-excited sensory nerve functions, comprising administering to a patient in need of treatment thereof an oral pharmaceutical composition comprising an effective amount of (2-Amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)(4-chlorophenyl) methanone or a pharmaceutically acceptable salt thereof in dosage levels of from 45 μg/kg to 1024 μg/kg.
A method of treating inflammatory pain, comprising administering to a mammal in need of treatment thereof a pharmaceutical composition comprising an effective amount of 2-Amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)(4-chlorophenyl)methanone or a pharmaceutically acceptable salt thereof.
A method of treating persistent chemical pain, comprising administering to a mammal in need of treatment thereof a pharmaceutical composition comprising an effective amount of (2-Amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)(4-chlorophenyl) methanone or a pharmaceutically acceptable salt thereof.
A method of treating pain states, comprising administering to a mammal in need of treatment thereof a pharmaceutical composition comprising an effective amount of (2-Amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)(4-chlorophenyl) methanone or a pharmaceutically acceptable salt thereof.
A pharmaceutical preparation for oral administration to a human for the reduction of pain states comprising (2-Amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)(4-chlorophenyl) methanone or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.